Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07052123
Recruiting Not applicable

Non-Invasive Blood Pressure Monitoring in ICU Patients Using the DARE Device

NCT07052123 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier de Saint-Denis
Phase
Not applicable
Started
2025-03-24
Last updated
2025-07-04

Condition(s) studied

HemodynamicsBlood Pressure MonitoringIntensive Care UnitsCritical IllnessMonitoring, Physiologic

Investigational drug(s) / intervention(s)

MultiSense® Non-Invasive Hemodynamic Monitoring Device

MultiSense® Non-Invasive Hemodynamic Monitoring Device: The MultiSense® device is a wireless, non-invasive monitoring system designed to continuously measure blood pressure, microcirculation, central body temperature, and detect arrhythmias in ICU patients. It aims to reduce risks associated with invasive monitoring, improve patient comfort and mobility, and decrease alarm fatigue through intelligent alert algorithms.

Study summary

This study tests a new non-invasive device called DARE to monitor blood pressure in patients in intensive care. It compares the device's readings to standard invasive methods and also looks at how well it measures other vital signs like temperature, oxygen levels, and heart rhythm. The goal is to improve patient safety and comfort while helping doctors detect problems earlier.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients (male or female), aged 18 years or older * Admitted to intensive care unit (ICU) or critical care with an expected hospital stay longer than 2 days * Equipped with an arterial catheter for invasive blood pressure monitoring * Equipped with a urinary catheter for invasive core body temperature monitoring Exclusion Criteria: * Patients under 18 years old (minors) * Known skin allergy to adhesives or silicone, or skin condition preventing adhesive use * History of extensive skin pathology (e.g., Lyell syndrome) * Patients with therapeutic limitations * Patients with active implanted medical devices (e.g., pacemaker, defibrillator) * Pregnant or breastfeeding women * Patients not affiliated with the French social security system * Patients or their legal representatives refusing consent, or unable to understand information and give informed consent * Patients under legal guardianship, curatorship, or deprived of liberty

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
France Saint-Denis France Recruiting

More Centre Hospitalier de Saint-Denis trials in France

Representation of Diet in the Management of Type 2 Diabetes in Migrant Patients at CHSD Recruiting
Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children" Recruiting
Medical Anthropology and Migrants in Precarious Situations, Cared for in Intensive and Post-intensive Care Units Starting soon
Community-acquired Pneumonia Due to Chlamydia Pneumoniae Starting soon
Geographic Analysis of Cancer Patients' Residences at Delafontaine Hospital Starting soon

Other trials for the same condition

Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection Recruiting
Geriatric Assessment at Discharge From the Intensive Care Unit in Patients Aged 75 Years and Older: a Feasibility Study Recruiting
Setting up a Warehouse of Physiological Data and Biomedical Signals in Adult Intensive Care Recruiting
IMMUNOREA - Immunological and Inflammatory Determinants Associated With the Prognosis of Intensive Care Patients Recruiting
Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07052123 on ClinicalTrials.gov ↗ ← All trials in France